Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy

Publication Date: July 27, 2020
Last Updated: March 22, 2022


Key Recommendations

Diagnosis

All patients with cancer anticipating systemic anticancer therapy should be tested for HBV by three tests prior to, or at the beginning of, systemic anticancer therapy:
  • hepatitis B surface antigen (HBsAg)
  • hepatitis B core antibody (anti-HBc) total immunoglobulin (Ig) or IgG
  • antibody to hepatitis B surface antigen (anti-HBs)
(EB, S, B)
Note: Anticancer therapy should not be delayed for the results of these screening tests. Findings of chronic HBV (HBsAg-positive) or past HBV (HBsAg-negative and anti-HBc-positive with either negative or positive anti-HBs) infection require reactivation risk assessment.
7341

Overview

Title

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy

Authoring Organization